Nxera Pharma Earns $10M Milestone as Neurocrine Wins FDA Acceptance for Alzheimer’s Phase 2 Study
Tokyo, Japan and Cambridge, UK — August 26, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences...
Neuropsychiatry
Advertisement
Alzamend Neuro Shares Lithium Imaging Data at Neuroscience 2026
Atlanta, Georgia, August 20, 2026 Alzamend Neuro, Inc. has announced that data from its Phase 1/2A clinical trial of...
LB Pharmaceuticals Accelerates Phase 3 LB-102 Schizophrenia Timeline
New York, July 22, 2026 LB Pharmaceuticals announced that it now expects to report topline results from the pivotal...
Cumulus and Muse Enhance CNS Clinical Trials
LONDON, UK, July 6, 2026 Cumulus Neuroscience announced a strategic collaboration with Muse by Interaxon to integrate validated at-home...
PureTech and Seaport Report Positive GlyphAgo Phase 1 Data
BOSTON, June 8, 2026 PureTech Health and its Founded Entity Seaport Therapeutics announced positive results from the multiple-ascending dose...
Advertisements
Galmed to Acquire Colospan in Major GI MedTech Expansion
RAMAT GAN, Israel – June 8, 2026 Galmed Pharmaceuticals has entered into a definitive agreement to acquire Colospan Ltd.,...
Neurocrine Presents New INGREZZA Data Showing Rapid Improvements in Tardive Dyskinesia
SAN DIEGO, California, USA – June 8, 2026 Neurocrine Biosciences has presented new clinician-reported data demonstrating meaningful functional, physical,...
Teva Advances Schizophrenia Therapy in Europe
TEL AVIV, Israel & PARIS, May 21, 2026 Teva Pharmaceuticals and Medincell have announced that the European Medicines Agency...
Johnson & Johnson Showcases Neuropsychiatry Data at APA 2026
TITUSVILLE, N.J., May 11, 2026 Johnson & Johnson announced the presentation of 18 new and encore abstracts highlighting the...
MapLight Therapeutics Completes Phase 2 CNS Trials Enrollment
SAN FRANCISCO & BOSTON, May 1, 2026 MapLight Therapeutics, Inc. announced the completion of enrollment in its Phase 2...
Advertisement
